Kasper W, Meinertz T, Hohnloser S, Engler H, Hasler C, Rössler W, Wolf H, Welzel D, Just H, Gurewich V
Innere Medizin, Universitätsklinik Freiburg i.Br.
Klin Wochenschr. 1988;66 Suppl 12:109-14.
Single-chain urokinase-type plasminogen activator (scu-PA), was given to 20 patients with acute myocardial infarction first alone (group I; n = 9) and then in combination with an initial bolus injection of 200,000 units of urokinase (group II; n = 11). In group I, scu-PA was administered in a dose of 15 mg up to 60 mg as an infusion over one hour. Complete reperfusion was achieved in 3/9 patients after 50 to 60 min and partial reperfusion in an additional 2 patients. In group II, a bolus injection of urokinase and 48 mg of scu-PA over one hour were given. Reperfusion was achieved in 9/11 patients after a mean of 30 +/- 22 min. Fibrinogen, alpha 2-anti-plasmin and plasminogen levels did not change from baseline in group I. In group II, fibrinogen levels decreased slightly from 272 +/- 84 mg% to 178 +/- 82 mg% (p less than 0.05) after two hours. No bleeding complications were encountered. Reocclusion at 24 hours was evaluated in 18 patients and was not seen. It was concluded that an initial bolus of urokinase improves the efficacy and the rate of thrombolysis by scu-PA.
将单链尿激酶型纤溶酶原激活剂(scu-PA)分别给予20例急性心肌梗死患者,先是单独给药(I组;n = 9),然后联合初始静脉推注20万单位尿激酶(II组;n = 11)。在I组中,scu-PA以15毫克至60毫克的剂量在1小时内静脉输注。50至60分钟后,9例患者中有3例实现完全再灌注,另有2例患者实现部分再灌注。在II组中,静脉推注尿激酶并在1小时内给予48毫克scu-PA。平均30±22分钟后,11例患者中有9例实现再灌注。I组中纤维蛋白原、α2-抗纤溶酶和纤溶酶原水平与基线相比无变化。在II组中,两小时后纤维蛋白原水平从272±84毫克%略有下降至178±82毫克%(p<0.05)。未出现出血并发症。对18例患者进行了24小时再闭塞评估,未发现再闭塞情况。得出的结论是,初始静脉推注尿激酶可提高scu-PA的溶栓疗效和速率。